Figure 3.
Overall survival (OS) was significantly worse in male MDS/AML patients treated with 5-azacytidine/decitabine. 90 MDS and 76 AML patients initiated on treatment between January 2002 and December 2007 at Cleveland Clinic with DNA available for sequencing analysis for the A79C SNP and verifiable survival annotation. A) OS in MDS/AML patients treated with 5-azacytidine or decitabine. B) OS in AML patients treated with cytarabine. These patients received induction cytarabine in combination with anthracycline, some received additional cycles of consolidation that included cytarabine.